Multidimensional Evidence Generation and FDA Regulatory Decision Making Defining and Using "Real-World" Data

被引：146
|
作者：
Jarow, Jonathan P. [1 ]
LaVange, Lisa [1 ]
Woodcock, Janet [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, WO51 RM6364,10903 New Hampshire Ave, Silver Spring, MD 20993 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 318卷 / 08期
关键词：
D O I：
10.1001/jama.2017.9991
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：703 / 704
页数：2
相关论文
共 50 条
  • [21] Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
    Jang, Ha Young
    Kim, In-Wha
    Oh, Jung Mi
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] The evolution of real-world evidence in healthcare decision making
    Williams, David M.
    Evans, Marc
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 443 - 445
  • [23] Real-world endpoints to support regulatory decision-making
    Christian, Jennifer B.
    Warren, Edward J.
    Cameron, David
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 427 - 427
  • [24] Real-World Evidence in the Real World: Beyond the FDA
    Krause, Joan H.
    Saver, Richard S.
    [J]. AMERICAN JOURNAL OF LAW & MEDICINE, 2018, 44 (2-3) : 161 - 179
  • [25] REPLACING RCTS WITH REAL WORLD DATA FOR REGULATORY DECISION MAKING RCTs and real world evidence are complementary, not alternatives
    Morales, Daniel R.
    Arlett, Peter
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 381
  • [26] Real-world evidence to support regulatory decision making: New or expanded medical product indications
    Franklin, Jessica M.
    Liaw, Kai-Li
    Iyasu, Solomon
    Critchlow, Cathy W.
    Dreyer, Nancy A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (06) : 685 - 693
  • [27] An Industry Perspective on Real-World Evidence in Regulatory Decision Making: An Example of Transparency in Pharmacoepidemiologic Research
    Weaver, James
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 34S - 37S
  • [28] FDA to Consider Real-World Evidence
    Caruso, Catherine
    [J]. CANCER DISCOVERY, 2019, 9 (03) : 310 - 310
  • [29] ASSESSMENT OF REAL-WORLD DATA SOURCES AND A HYBRID APPROACH IN REAL-WORLD EVIDENCE GENERATION USING UNHARMONIZED DATA SOURCES
    Toh, K. C.
    Goh, C. H.
    Goh, V
    Dong, Z.
    Dumpala, L. S.
    Maity, S.
    Wu, J. Y.
    Kleinman, N.
    Lee, Y.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S407 - S407
  • [30] The use of real-world data/evidence in regulatory submissions
    Song, Fuyu
    Zang, Chenxuan
    Ma, Xinyi
    Hu, Sifan
    Sun, Qiqing
    Chow, Shein-Chung
    Sun, Hongqiang
    [J]. CONTEMPORARY CLINICAL TRIALS, 2021, 109
12345